Recurrent Cancer Clinical Trials
2 recruiting trials for Recurrent Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Recurrent Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 / Phase 2 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Immatics US, Inc. (1), Australian & New Zealand Children's Haematology/Oncology Group (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is IMA203 Product (biological, 1 trial), followed by IMA203 product- flat dose, IMA203CD8 Product.
Track Recurrent Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express...
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Recurrent Cancer, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Recurrent Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Recurrent Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.